Sulfinpyrazone (BioDeep_00000006468)

 

Secondary id: BioDeep_00001867806

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione

化学式: C23H20N2O3S (404.1195)
中文名称: 苯磺保泰松
谱图信息: 最多检出来源 Homo sapiens(urine) 18.63%

分子结构信息

SMILES: C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
InChI: InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

描述信息

Sulfinpyrazone is only found in individuals that have used or taken this drug. It is a uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [PubChem]Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).
M - Musculo-skeletal system > M04 - Antigout preparations > M04A - Antigout preparations > M04AB - Preparations increasing uric acid excretion
D018501 - Antirheumatic Agents > D006074 - Gout Suppressants > D014528 - Uricosuric Agents
C26170 - Protective Agent > C921 - Uricosuric Agent

同义名列表

28 个代谢物同义名

4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione; 4-(2-Benzenesulphinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulphinylethyl)pyrazolidine; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2-phenylsulphinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-phenylsulfinethyl)-3,5-pyrazolidinedione; Novartis brand OF sulfinpyrazone; Nu pharm brand OF sulfinpyrazone; Nu-pharm brand OF sulfinpyrazone; Apotex brand OF sulfinpyrazone; Sulphoxyphenylpyrazolidine; Sulfoxyphenylpyrazolidine; Sulfoxyphenylpyrazolidin; (+/-)-Sulfinpyrazone; Apo-sulfinpyrazone; Apo sulfinpyrazone; Nu-sulfinpyrazone; Nu sulfinpyrazone; Diphenylpyrazone; Sulphinpyrazone; sulfinpyrazone; Sulfinpyrazine; Sulfinpyrazon; Usaf ge-13; Anturane; Anturan; Sulfinpyrazone



数据库引用编号

16 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 9 ABCB1, ALB, AXIN2, CYP3A4, ELANE, HPGDS, PF4, SLC23A2, XDH
Endoplasmic reticulum membrane 4 CYP3A4, UGT1A4, UGT1A9, UGT2B7
Nucleus 2 ALB, AXIN2
cytosol 5 ALB, AXIN2, ELANE, HPGDS, XDH
phagocytic vesicle 1 ELANE
centrosome 2 ALB, AXIN2
nucleoplasm 1 HPGDS
Cell membrane 2 ABCB1, SLC23A2
Multi-pass membrane protein 5 ABCB1, ABCC2, ABCC3, SLC23A2, SLC45A2
cell surface 3 ABCB1, ABCC2, ELANE
Golgi apparatus 1 ALB
Golgi membrane 1 INS
plasma membrane 8 ABCB1, ABCC2, ABCC3, AXIN2, F2, REN, SERPINC1, SLC23A2
Membrane 10 ABCB1, ABCC2, ABCC3, CYP3A4, REN, SLC23A2, SLC45A2, UGT1A4, UGT1A9, UGT2B7
apical plasma membrane 3 ABCB1, ABCC2, SLC23A2
basolateral plasma membrane 2 ABCC3, SLC23A2
extracellular exosome 5 ABCB1, ALB, ELANE, F2, SERPINC1
endoplasmic reticulum 3 ALB, UGT1A4, UGT1A9
extracellular space 9 ALB, ELANE, F2, INS, PF4, PPBP, REN, SERPINC1, XDH
intercellular canaliculus 1 ABCC2
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 2 CYP3A4, HPGDS
Microsome membrane 1 CYP3A4
Secreted 5 ALB, F2, INS, PF4, REN
extracellular region 8 ALB, ELANE, F2, INS, PF4, PPBP, REN, SERPINC1
Single-pass membrane protein 3 UGT1A4, UGT1A9, UGT2B7
anchoring junction 1 ALB
beta-catenin destruction complex 1 AXIN2
Melanosome membrane 1 SLC45A2
apical part of cell 1 REN
Apical cell membrane 2 ABCB1, ABCC2
Peroxisome 1 XDH
sarcoplasmic reticulum 1 XDH
collagen-containing extracellular matrix 4 ELANE, F2, PF4, SERPINC1
secretory granule 1 ELANE
ciliary basal body 1 ALB
centriole 1 ALB
Secreted, extracellular space 1 SERPINC1
spindle pole 1 ALB
blood microparticle 3 ALB, F2, SERPINC1
Basolateral cell membrane 1 ABCC3
endosome lumen 1 INS
basal plasma membrane 2 ABCC3, SLC23A2
secretory granule lumen 1 INS
Golgi lumen 2 F2, INS
endoplasmic reticulum lumen 4 ALB, F2, INS, SERPINC1
transcription repressor complex 1 ELANE
platelet alpha granule lumen 3 ALB, PF4, PPBP
specific granule lumen 1 ELANE
tertiary granule lumen 1 PPBP
transport vesicle 1 INS
azurophil granule lumen 1 ELANE
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
Basal cell membrane 1 ABCC3
external side of apical plasma membrane 1 ABCB1
Cytoplasmic vesicle, phagosome 1 ELANE
ciliary transition fiber 1 ALB


文献列表

  • Xiang-Ning Su, Chuan-Ying Li, Yu-Ping Zhang. Chlorpyrifos and chlorfenapyr resistance in Spodoptera frugiperda (Lepidoptera: Noctuidae) relies on UDP-glucuronosyltransferases. Journal of economic entomology. 2023 May; ?(?):. doi: 10.1093/jee/toad088. [PMID: 37253084]
  • Ayman Abo Elmaaty, Mohammed I A Hamed, Muhammad I Ismail, Eslam B Elkaeed, Hamada S Abulkhair, Muhammad Khattab, Ahmed A Al-Karmalawy. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Molecules (Basel, Switzerland). 2021 Jun; 26(12):. doi: 10.3390/molecules26123772. [PMID: 34205704]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Alexander F Flynn, M Gordon Joyce, Rebekah T Taylor, Sasisekhar Bennuru, Alyssa R Lindrose, Spencer L Sterling, C Paul Morris, Thomas B Nutman, Edward Mitre. Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis. PLoS neglected tropical diseases. 2019 09; 13(9):e0007687. doi: 10.1371/journal.pntd.0007687. [PMID: 31513587]
  • Andrew Rowland, David Hallifax, Matthew R Nussio, Joseph G Shapter, Peter I Mackenzie, J Brian Houston, Kathleen M Knights, John O Miners. Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins. Xenobiotica; the fate of foreign compounds in biological systems. 2015; 45(10):847-57. doi: 10.3109/00498254.2015.1021403. [PMID: 25801059]
  • Ho Jung Shin, Michio Takeda, Atsushi Enomoto, Masaaki Fujimura, Hiroki Miyazaki, Naohiko Anzai, Hitoshi Endou. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton, Vic.). 2011 Feb; 16(2):156-62. doi: 10.1111/j.1440-1797.2010.01368.x. [PMID: 21272127]
  • David Buttar, Nicola Colclough, Stefan Gerhardt, Philip A MacFaul, Scott D Phillips, Alleyn Plowright, Paul Whittamore, Kin Tam, Klaus Maskos, Stefan Steinbacher, Holger Steuber. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. Bioorganic & medicinal chemistry. 2010 Nov; 18(21):7486-96. doi: 10.1016/j.bmc.2010.08.052. [PMID: 20869876]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Kajsa P Kanebratt, Tommy B Andersson. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jan; 36(1):137-45. doi: 10.1124/dmd.107.017418. [PMID: 17954527]
  • Zhifeng Yu, Wing Ping Fong, Christopher H K Cheng. Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug metabolism and disposition: the biological fate of chemicals. 2007 Jun; 35(6):981-6. doi: 10.1124/dmd.106.012187. [PMID: 17325024]
  • Sharon L Ripp, Jessica B Mills, Odette A Fahmi, Kristen A Trevena, Jennifer L Liras, Tristan S Maurer, Sonia M de Morais. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug metabolism and disposition: the biological fate of chemicals. 2006 Oct; 34(10):1742-8. doi: 10.1124/dmd.106.010132. [PMID: 16837568]
  • Dermot F McGinnity, James Tucker, Steve Trigg, Robert J Riley. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2005 Nov; 33(11):1700-7. doi: 10.1124/dmd.105.005884. [PMID: 16081671]
  • Kelly A Best, Melanie E Holmes, Sue E Samson, James Mwanjewe, John X Wilson, S Jeffrey Dixon, Ashok K Grover. Ascorbate uptake in pig coronary artery endothelial cells. Molecular and cellular biochemistry. 2005 Mar; 271(1-2):43-9. doi: 10.1007/s11010-005-3442-0. [PMID: 15881654]
  • Yoko Honda, Fumihiko Ushigome, Noriko Koyabu, Satoshi Morimoto, Yukihiro Shoyama, Takeshi Uchiumi, Michihiko Kuwano, Hisakazu Ohtani, Yasufumi Sawada. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. British journal of pharmacology. 2004 Dec; 143(7):856-64. doi: 10.1038/sj.bjp.0706008. [PMID: 15504753]
  • Pascal H E Smeets, Rémon A M H van Aubel, Alfons C Wouterse, Jeroen J M W van den Heuvel, Frans G M Russel. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. Journal of the American Society of Nephrology : JASN. 2004 Nov; 15(11):2828-35. doi: 10.1097/01.asn.0000143473.64430.ac. [PMID: 15504935]
  • Helene Sabia, Gangadhar Sunkara, Monica Ligueros-Saylan, Yibin Wang, Harold Smith, James McLeod, Pratapa Prasad. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. European journal of clinical pharmacology. 2004 Aug; 60(6):407-12. doi: 10.1007/s00228-004-0778-4. [PMID: 15197517]
  • Pamela K Smitherman, Alan J Townsend, Timothy E Kute, Charles S Morrow. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. The Journal of pharmacology and experimental therapeutics. 2004 Jan; 308(1):260-7. doi: 10.1124/jpet.103.057729. [PMID: 14569069]
  • Zhe-Sheng Chen, Elizabeth Hopper-Borge, Martin G Belinsky, Irina Shchaveleva, Elena Kotova, Gary D Kruh. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Molecular pharmacology. 2003 Feb; 63(2):351-8. doi: 10.1124/mol.63.2.351. [PMID: 12527806]
  • Shawn D Flanagan, Carolyn L Cummins, Miki Susanto, Xiaoli Liu, Lori H Takahashi, Leslie Z Benet. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002; 64(3):126-34. doi: 10.1159/000056161. [PMID: 11834888]
  • A L Caforio, A Gambino, F Tona, G Feltrin, F Marchini, E Pompei, L Testolin, A Angelini, S Dalla Volta, D Casarotto. Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2000 Dec; 19(12):1205-8. doi: 10.1016/s1053-2498(00)00216-3. [PMID: 11124491]
  • R Evers, M de Haas, R Sparidans, J Beijnen, P R Wielinga, J Lankelma, P Borst. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. British journal of cancer. 2000 Aug; 83(3):375-83. doi: 10.1054/bjoc.2000.1262. [PMID: 10917554]
  • J Wijnholds, C A Mol, L van Deemter, M de Haas, G L Scheffer, F Baas, J H Beijnen, R J Scheper, S Hatse, E De Clercq, J Balzarini, P Borst. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jun; 97(13):7476-81. doi: 10.1073/pnas.120159197. [PMID: 10840050]
  • K Lin, W Sadée, J M Quillan. Rapid measurements of intracellular calcium using a fluorescence plate reader. BioTechniques. 1999 Feb; 26(2):318-22, 324. doi: 10.2144/99262rr02. [PMID: 10023544]
  • M Walls, S Goral, W Stone. Acute renal failure due to sulfinpyrazone. The American journal of the medical sciences. 1998 May; 315(5):319-21. doi: 10.1097/00000441-199805000-00007. [PMID: 9587090]
  • C Catalano, F Fabbian, V Bordin, D Di Landro. Mycophenolate mofetil toxicity in an anorexic kidney transplant patient treated with sulphinpirazone. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1997 Nov; 12(11):2467-8. doi: 10.1093/ndt/12.11.2467b. [PMID: 9394357]
  • F Roch-Ramel, B Guisan, J Diezi. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. The Journal of pharmacology and experimental therapeutics. 1997 Feb; 280(2):839-45. doi: . [PMID: 9023298]
  • A Gleixner, H Sauerwein, H H Meyer. Probenecid, sulfinpyrazone and pyrazinamide do not inhibit urinary excretion of the beta 2-adrenoceptor agonist clenbuterol in cattle. Food additives and contaminants. 1996 Aug; 13(6):603-8. doi: 10.1080/02652039609374445. [PMID: 8871117]
  • J X Wilson, S J Dixon, J Yu, S Nees, K Tyml. Ascorbate uptake by microvascular endothelial cells of rat skeletal muscle. Microcirculation (New York, N.Y. : 1994). 1996 Jun; 3(2):211-21. doi: 10.3109/10739689609148290. [PMID: 8839443]
  • M He, K L Kunze, W F Trager. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug metabolism and disposition: the biological fate of chemicals. 1995 Jun; 23(6):659-63. doi: NULL. [PMID: 7587949]
  • S C Lee, A G Renwick. Sulphoxide reduction by rat and rabbit tissues in vitro. Biochemical pharmacology. 1995 May; 49(11):1557-65. doi: 10.1016/0006-2952(95)00092-e. [PMID: 7786296]
  • S C Lee, A G Renwick. Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro. Biochemical pharmacology. 1995 May; 49(11):1567-76. doi: 10.1016/0006-2952(95)00093-f. [PMID: 7786297]
  • P G Conaghan, R O Day. Risks and benefits of drugs used in the management and prevention of gout. Drug safety. 1994 Oct; 11(4):252-8. doi: 10.2165/00002018-199411040-00004. [PMID: 7848545]
  • M S Tasende, G R Gale, A B Smith, M M Jones, P K Singh. Monoisoamyl meso-2,3-dimercaptosuccinate: interaction with metallothionein-bound cadmium in vitro and evidence of active transport into renal and hepatic cells in vivo. Research communications in chemical pathology and pharmacology. 1992 Jun; 76(3):323-39. doi: NULL. [PMID: 1636055]
  • C M Florkowski, G W Ching, R E Ferner. Acute non-oliguric renal failure secondary to sulphinpyrazone overdose. Journal of clinical pharmacy and therapeutics. 1992 Feb; 17(1):71. doi: 10.1111/j.1365-2710.1992.tb01269.x. [PMID: 1548318]
  • S J Dixon, A Kulaga, E M Jaworski, J X Wilson. Ascorbate uptake by ROS 17/2.8 osteoblast-like cells: substrate specificity and sensitivity to transport inhibitors. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1991 Jun; 6(6):623-9. doi: 10.1002/jbmr.5650060613. [PMID: 1887825]
  • F Nagy. Use of Rabenid for different indications. Therapia Hungarica (English edition). 1991; 39(2):90-2. doi: NULL. [PMID: 1948784]
  • A Kumar, Y N Singh, A N Malaviya, K Chaudhary, S Tripathy. Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India. The Journal of the Association of Physicians of India. 1990 Jun; 38(6):400-2. doi: NULL. [PMID: 2384454]
  • A Grzegorzewska, K Antoniewicz, J Kuźniak, E Zawadzka. [Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis]. Przeglad lekarski. 1990; 47(10):686-90. doi: NULL. [PMID: 2089444]
  • D R Janero, B Burghardt, R Lopez, M Cardell. Influence of cardioprotective cyclooxygenase and lipoxygenase inhibitors on peroxidative injury to myocardial-membrane phospholipid. Biochemical pharmacology. 1989 Dec; 38(24):4381-7. doi: 10.1016/0006-2952(89)90646-1. [PMID: 2557848]
  • M D Stevens, E J Miller, A B Cohen. Search for drugs that may reduce the load of neutrophil azurophilic granule enzymes in the lungs of patients with emphysema. Experimental lung research. 1989 Jul; 15(4):663-80. doi: 10.3109/01902148909069625. [PMID: 2548834]
  • F Di Virgilio, C Fasolato, T H Steinberg. Inhibitors of membrane transport system for organic anions block fura-2 excretion from PC12 and N2A cells. The Biochemical journal. 1988 Dec; 256(3):959-63. doi: 10.1042/bj2560959. [PMID: 3223965]
  • H Iven, H Brasch. The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer chemotherapy and pharmacology. 1988; 21(4):337-42. doi: 10.1007/bf00264201. [PMID: 3370743]
  • L D Heimark, S Toon, M Gibaldi, W F Trager, R A O'Reilly, D A Goulart. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans. Clinical pharmacology and therapeutics. 1987 Sep; 42(3):312-9. doi: 10.1038/clpt.1987.154. [PMID: 3621786]
  • H A Strong, A G Renwick, C F George, Y F Liu, M J Hill. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica; the fate of foreign compounds in biological systems. 1987 Jun; 17(6):685-96. doi: 10.3109/00498258709043976. [PMID: 3630204]
  • G J del Zoppo. Antiplatelet therapy in thrombotic thrombocytopenic purpura. Seminars in hematology. 1987 Apr; 24(2):130-9. doi: NULL. [PMID: 2440111]
  • M Sanchez Bayle, M Vazquez Martul, J L Ecija Peiro, C Garcia Vao, C Ramo Mancheño. Renal handling of uric acid in normal children by means of the pyrazinamide and sulfinpyrazone tests. The International journal of pediatric nephrology. 1987 Jan; 8(1):5-8. doi: NULL. [PMID: 3583558]
  • K Opatrný, V Cepelák, K Opatrný, J Valenta, H Cepeláková, F Sefrna. [Personal experience with the administration of sulfinpyrazone to patients with kidney failure]. Vnitrni lekarstvi. 1986 Jul; 32(7):673-80. doi: NULL. [PMID: 3526712]
  • S Chow, J Roscoe, D C Cattran. Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1986 May; 7(5):407-12. doi: 10.1016/s0272-6386(86)80090-7. [PMID: 3085480]
  • J Boelaert, P Lijnen, E Robbens, A Rocher, R Daneels, M Schurgers, A Amery. Impairment of renal function due to sulphinpyrazone after coronary artery bypass surgery: a prospective double-blind study. Journal of cardiovascular pharmacology. 1986 Mar; 8(2):386-91. doi: 10.1097/00005344-198603000-00023. [PMID: 2422479]
  • M Sanchez Bayle, C Garcia-Vao, C Ramo Mancheño, M Vazquez Martul, J L Ecija Peiro. Hyperuricemia and increase in postsecretory reabsorption of uric acid. Nephron. 1986; 43(2):151-2. doi: 10.1159/000183817. [PMID: 3713945]
  • S Toon, L K Low, M Gibaldi, W F Trager, R A O'Reilly, C H Motley, D A Goulart. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clinical pharmacology and therapeutics. 1986 Jan; 39(1):15-24. doi: 10.1038/clpt.1986.3. [PMID: 3943265]
  • E G Lentjes, F G Russel, C A van Ginneken. Renal clearance of sulphinpyrazone in man. European journal of clinical pharmacology. 1986; 31(4):473-8. doi: 10.1007/bf00613527. [PMID: 3816927]
  • E G Lentjes, Y Tan, C A Van Ginneken. Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography. Pharmaceutisch weekblad. Scientific edition. 1985 Dec; 7(6):252-9. doi: 10.1007/bf01959198. [PMID: 4080510]
  • C Patrono, G Ciabattoni, P Patrignani, F Pugliese, P Filabozzi, F Catella, G Davì, L Forni. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 Dec; 72(6):1177-84. doi: 10.1161/01.cir.72.6.1177. [PMID: 3933848]
  • J O Miners, J Attwood, L M Wing, D J Birkett. Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man. Drug metabolism and disposition: the biological fate of chemicals. 1985 Sep; 13(5):598-601. doi: . [PMID: 2865110]
  • G Bertolini, P Naliato, C Borghi. [Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]]. Minerva medica. 1985 Aug; 76(32-33):1463-7. doi: NULL. [PMID: 4034045]
  • L Bertoli, I Busnardo, C Borghi, P Zagnoni. Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment. Pharmacological research communications. 1985 Mar; 17(3):299-306. doi: 10.1016/0031-6989(85)90105-5. [PMID: 4011651]
  • L M Wing, J O Miners, K J Lillywhite. Verapamil disposition--effects of sulphinpyrazone and cimetidine. British journal of clinical pharmacology. 1985 Mar; 19(3):385-91. doi: 10.1111/j.1365-2125.1985.tb02658.x. [PMID: 3986090]
  • D G Wyse. Dose-related cardiac electrophysiologic effects of sulfinpyrazone. Clinical pharmacology and therapeutics. 1985 Feb; 37(2):166-73. doi: 10.1038/clpt.1985.30. [PMID: 3967460]
  • B Lo. Hyperuricemia and gout. The Western journal of medicine. 1985 Jan; 142(1):104-7. doi: NULL. [PMID: 3976216]
  • C Patrono, G Ciabattoni, P Filabozzi, F Catella, L Forni, M Segni, P Patrignani, F Pugliese, B M Simonetti, A Pierucci. Drugs, prostaglandins, and renal function. Advances in prostaglandin, thromboxane, and leukotriene research. 1985; 13(?):131-9. doi: NULL. [PMID: 2988308]
  • F Schlicht, C Staiger, J de Vries, U Gundert-Remy, R Hildebrandt, J Harenberg, N S Wang, E Weber. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. European journal of clinical pharmacology. 1985; 28(1):97-103. doi: 10.1007/bf00635715. [PMID: 3987792]
  • C Boschetti, M Cortellaro, F Invernizzi, P Massaro, A Rigolone, E Polli. Treatment with sulfinpyrazone of essential mixed cryoglobulinemia. Bollettino dell'Istituto sieroterapico milanese. 1985; 64(1):55-8. doi: . [PMID: 3159402]
  • A K Pedersen, G A FitzGerald. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clinical pharmacology and therapeutics. 1985 Jan; 37(1):36-42. doi: 10.1038/clpt.1985.8. [PMID: 3917387]
  • J Grunwald, C C Haudenschild. The influence of antiplatelet drugs on injury-stimulated migration of cultured smooth muscle cells. Artery. 1985; 12(5):324-36. doi: NULL. [PMID: 4051753]
  • J B Dossetor, T Kovithavongs, M Salkie, J Preiksaitis. Cyclosporine-associated lymphoproliferation, despite controlled cyclosporine blood concentrations, in a renal allograft recipient. Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress. 1985; 21(?):1021-6. doi: NULL. [PMID: 2986094]
  • P Lijnen. [Prostaglandin studies in normal subjects and in post-myocardial infarct patients]. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie. 1985; 47(1):49-62. doi: NULL. [PMID: 3859958]
  • B Rosenkranz, G Fejes-Tóth, U Diener, J C Frölich. Effects of sulfinpyrazone on renal function and prostaglandin formation in man. Nephron. 1985; 39(3):237-43. doi: 10.1159/000183378. [PMID: 3883211]
  • G Decaux, I Dumont, Y Waterlot, B Hanson. Mechanisms of hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. Nephron. 1985; 39(3):164-8. doi: 10.1159/000183365. [PMID: 3974780]
  • S Toon, W F Trager. Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone. Journal of pharmaceutical sciences. 1984 Nov; 73(11):1671-3. doi: 10.1002/jps.2600731154. [PMID: 6520783]
  • Y K Tam, S M Ferguson, M L Yau, D G Wyse. Simple and rapid high-performance liquid chromatographic method for the analysis of sulfinpyrazone and four of its metabolites in human plasma. Journal of chromatography. 1984 Oct; 310(2):438-44. doi: 10.1016/0378-4347(84)80113-9. [PMID: 6511862]
  • F G Larsen, C G Larsen, R Brodersen. Warfarin-sulfinpyrazone interaction on binding to human serum albumin. The Journal of pharmacy and pharmacology. 1984 Oct; 36(10):689-90. doi: 10.1111/j.2042-7158.1984.tb04845.x. [PMID: 6150088]
  • H A Strong, A G Renwick, C F George. The site of reduction of sulphinpyrazone in the rabbit. Xenobiotica; the fate of foreign compounds in biological systems. 1984 Oct; 14(10):815-26. doi: 10.3109/00498258409151480. [PMID: 6506754]
  • H A Strong, J Oates, J Sembi, A G Renwick, C F George. Role of the gut flora in the reduction of sulfinpyrazone in humans. The Journal of pharmacology and experimental therapeutics. 1984 Sep; 230(3):726-32. doi: NULL. [PMID: 6470977]
  • E Strobl-Jäger, J Kaliman, H Sinzinger. Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor. Prostaglandins, leukotrienes, and medicine. 1984 Aug; 15(2):241-50. doi: 10.1016/0262-1746(84)90181-1. [PMID: 6436832]
  • G P Lewis, J R Smith. Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo. Prostaglandins. 1984 Jul; 28(1):29-41. doi: 10.1016/0090-6980(84)90111-4. [PMID: 6435186]
  • J Godbillon, J P Schoeller, S Gauron, G Gosset, J P Fillastre. Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report. British journal of clinical pharmacology. 1984 Jul; 18(1):107-8. doi: 10.1111/j.1365-2125.1984.tb05033.x. [PMID: 6743484]
  • A Del Maschio, M Livio, C Cerletti, G De Gaetano. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites. European journal of pharmacology. 1984 Jun; 101(3-4):209-14. doi: 10.1016/0014-2999(84)90158-4. [PMID: 6432556]
  • M Cortellaro, C Boschetti, V Antoniazzi, E E Polli, G de Gaetano, A De Blasi, M Gerna, L Pezzi, S Garattini. A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers. Thrombosis research. 1984 Apr; 34(1):65-74. doi: 10.1016/0049-3848(84)90106-3. [PMID: 6729769]
  • J Boelaert, M Schurgers, R Daneels, P Lijnen, A Amery. Sulfinpyrazone: risk for renal insufficiency. Archives of internal medicine. 1984 Mar; 144(3):648-9. doi: NULL. [PMID: 6703838]
  • J Boelaert, P Lijnen, C Bulpitt, M Schurgers, R Daneels, A Amery. Impairment of renal function in post-myocardial infarct patients treated with sulfinpyrazone. European journal of clinical pharmacology. 1984; 26(3):409-10. doi: 10.1007/bf00548777. [PMID: 6734704]
  • C Prior, H Kirchmair. [Acute interstitial nephritis and kidney failure requiring dialysis after sulfinpyrazone therapy]. Acta medica Austriaca. 1984; 11(2):55-9. doi: . [PMID: 6234742]
  • E Palummeri, C Borghi, R Di Ruvo, L Dacco', M Passeri. Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule. The Journal of international medical research. 1984; 12(5):271-6. doi: 10.1177/030006058401200501. [PMID: 6500166]
  • D Docci, M Mambelli, G Manzoni, F Turci, G Salvi. Acute renal failure secondary to sulfinpyrazone treatment after myocardial infarction. Nephron. 1984; 37(3):213-4. doi: 10.1159/000183248. [PMID: 6738772]
  • B S Kuo, L A Kaplan, W A Ritschel. High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma. Arzneimittel-Forschung. 1984; 34(5):548-50. doi: NULL. [PMID: 6540568]
  • M Cortellaro, C Boschetti, V Antoniazzi, G Moreo, S Repetto, E Verna, M Boscarini, A Limido, G Binaghi, E E Polli. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. Thrombosis and haemostasis. 1983 Dec; 50(4):857-9. doi: . [PMID: 6665767]
  • V Wizemann, P Buddensiek, J de Boor, S Grebe, G Schütterle. Gastrointestinal blood loss in patients undergoing maintenance dialysis. Kidney international. Supplement. 1983 Dec; 16(?):S218-20. doi: NULL. [PMID: 6588252]
  • L A Harker, J M Harlan, R Ross. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circulation research. 1983 Dec; 53(6):731-9. doi: 10.1161/01.res.53.6.731. [PMID: 6640860]
  • J X de Vries, C Staiger, N S Wang, F Schlicht. Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high-performance liquid chromatography. Journal of chromatography. 1983 Oct; 277(?):408-13. doi: 10.1016/s0378-4347(00)84867-7. [PMID: 6643630]
  • G Orlandini, M Brognoli. Acute renal failure and treatment with sulfinpyrazone. Clinical nephrology. 1983 Sep; 20(3):161-2. doi: NULL. [PMID: 6627766]
  • D Docci, F Turci, G Salvi. Sulfinpyrazone-associated acute renal failure. Clinical nephrology. 1983 Jul; 20(1):53. doi: NULL. [PMID: 6883821]
  • R A Morin, W H Lyness. Potentiation of morphine analgesia after pretreatment with probenecid or sulfinpyrazone. Pharmacology, biochemistry, and behavior. 1983 Jun; 18(6):885-9. doi: 10.1016/s0091-3057(83)80010-0. [PMID: 6889417]
  • D J Birkett, J O Miners, J Attwood. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. British journal of clinical pharmacology. 1983 May; 15(5):567-9. doi: 10.1111/j.1365-2125.1983.tb02093.x. [PMID: 6860533]
  • C Mahony, K M Wolfram, P V Nash, T D Bjornsson. Kinetics and metabolism of sulfinpyrazone. Clinical pharmacology and therapeutics. 1983 Apr; 33(4):491-7. doi: 10.1038/clpt.1983.67. [PMID: 6831828]
  • A C de Boer, P Han, A G Turpie, R Butt, M Gent, E Genton. Platelet tests and antiplatelet drugs in coronary artery disease. Circulation. 1983 Mar; 67(3):500-4. doi: 10.1161/01.cir.67.3.500. [PMID: 6217921]
  • P Lijnen, J Boelaert, P van Eeghem, R Daneels, M Schurgers, P de Jaegere, E van der Stichele, J Vincke, R Fagard, L J Verschueren, A Amery. Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction. Clinical nephrology. 1983 Mar; 19(3):143-6. doi: NULL. [PMID: 6340878]
  • I Dumont, G Decaux. Hypouricemia related to a hypersecretional tubulopathy. Nephron. 1983; 34(4):256-9. doi: 10.1159/000183025. [PMID: 6877462]